GE HealthCare Technologies (NASDAQ:GEHC) reported financial results for the first quarter ended March 31, 2026, revealing a complex landscape of steady demand offset by operational hurdles and macroeconomic pressures.
The Chicago-based medtech leader posted total revenue growth of 7.4%, including organic revenue growth of 2.9%, as global healthcare systems continued to invest in imaging and diagnostic infrastructure.
The company’s commercial momentum remained visible in its order book, with total organic orders up 1.1% against a difficult prior-year comparison of 10.3% growth.
GE HealthCare ended the quarter with a robust book-to-bill ratio of 1.07 times and a total backlog of $21.8 billion, providing significant visibility for the remainder of the fiscal year.
However, profitability in the quarter faced specific challenges.
The company reported a net income margin of 7.6% and an adjusted EBIT margin of 13.5%.
These figures were impacted by a discrete supplier issue within the Pharmaceutical Diagnostics (PDx) segment.
While management confirmed the issue has since been resolved, the disruption, coupled with more pronounced inflationary pressures, led to a diluted EPS of $0.85 and an Adjusted EPS of $0.99.
On the cash front, GE HealthCare generated $290 million in cash flow from operating activities and $112 million in free cash flow.
In response to the intensifying inflationary environment observed during the quarter, the company took the proactive step of reducing its full-year 2026 outlook for both profit and free cash flow.
Despite these adjustments, the firm still expects to deliver mid-to-high-single-digit adjusted EPS growth for the year, underpinned by healthy global end-market demand.